Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells

Authors: Ting Zhou, Jingjing Duan, Yan Wang, Xin Chen, Ganping Zhou, Rongkan Wang, Liwu Fu, Feng Xu

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

Multidrug resistance (MDR) is the main obstacle in breast cancer chemotherapy, a reversal reagent with high reversal effect but low toxicity is the hotpot issue at present. The antidepressant fluoxetine (FLX) is a new highly effective chemosensitizer; however, the possible mechanism of FLX in reversal of MDR is unclear. In this study, the effect of FLX on MDR mediated by apoptosis was researched in resistant/sensitive breast cancer cells, which treated by FLX/adriamycin (ADM)/paclitaxel (PTX) alone or FLX–ADM, FLX–PTX combination. Apoptosis assay demonstrated that FLX combined with ADM enhanced the proportion of apoptosis remarkably in MCF-7/ADM but not MCF-7 cells; however, increased the apoptosis rates in both cells when FLX–PTX combination. Results of apoptosis proteins assay showed a upgrade of p53 and a downgrade of Bcl-2 level by FLX–ADM or FLX–PTX combinations in both cells. Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell’s resistance and enhance the chemosensitivity to ADM and PTX.
Literature
1.
2.
Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 2000;65:95–106.
3.
O'Connor R. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets. 2009;9:273–80.CrossRefPubMed
4.
Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007;6(22):2782–7.CrossRefPubMed
5.
Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002;62:354–62.CrossRefPubMed
6.
Rathinasamy K, Jindal B, Asthana J, Singh P, Balaji PV, Panda D. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. BMC Cancer. 2010;10:213.CrossRefPubMedPubMedCentral
7.
Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol. 2010;63(3):204–9.CrossRefPubMed
8.
Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, et al. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull. 2007;30(8):1400–6.CrossRefPubMed
9.
Desoise B. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res. 1994;14:2291–4.
10.
Bush JA, Li G. Cancer chemoresistance: the relationship between P53 and multidrug transporters. Int J Cancer. 2002;98:323–30.CrossRefPubMed
11.
Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934–49.CrossRefPubMed
12.
Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411–24.CrossRefPubMed
13.
Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:23–30.CrossRefPubMed
14.
Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry. 1990;51:12–7.PubMed
15.
Cheer SM, Goa KL. Fluoxetine. A review of its therapeutic potential in the treatment of depression with physical illness. Drugs. 2001;61:81–110.CrossRefPubMed
16.
Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996;94(3):205–10.CrossRefPubMed
17.
Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008;112:197–201.CrossRefPubMed
18.
Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64:7562–9.CrossRefPubMed
19.
Choi MR, Oh DH, Kim SH, Yang BH, Lee JS, Choi J, et al. Fluoxetine up-regulates bcl-xL expression in rat c6 glioma cells. Psychiatry Investig. 2011;8:161–8.CrossRefPubMedPubMedCentral
20.
Fumagalli F, Molteni R, Calabrese F, Frasca A, Racagni G, Riva MA. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem. 2005;93:1551–60.CrossRefPubMed
21.
Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Invest Drugs. 2002;3:1652–9.
22.
Kars MD, Işeri OD, Gunduz U, Molnar J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy. 2008;54:194–200.CrossRefPubMed
23.
Steingart AB, Cotterchio M. Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol. 1995;48:1407–12.CrossRefPubMed
24.
Freire-Garabal M, Núñez MJ, Pereiro D, Riveiro P, Losada C, Fernández-Rial JC, et al. Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci. 1998;63:31–8.CrossRef
25.
Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006;237:180–7.CrossRefPubMed
26.
Argov M, Kashi R, Peer D, Margalit R. Treatment of resistant human colon cancer xenograftsby a fluoxetine–doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett. 2009;274:118–25.CrossRefPubMed
27.
Ong JC, Sun F, Chan E. Development of stealth liposome coencapsulating doxorubicin and fluoxetine. J Liposome Res. 2011;21(4):261–71.CrossRefPubMed
28.
Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood. 2003;101(8):3212–9.CrossRefPubMed
29.
Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt’s lymphoma. Int J Cancer. 2011;128:1712–23.CrossRefPubMed
30.
Hait WN. JM Yang. The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc. 2006;117:85–101.PubMedPubMedCentral
31.
Lee CS, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclearfactor-kappaB. Basic Clin Pharmacol Toxicol. 2010;106:446–53.CrossRefPubMed
32.
Djordjevic J, Djordjevic A, Adzic M, Elaković I, Matić G, Radojcic MB. Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver. Eur J Pharmacol. 2011;659:61–6.CrossRefPubMed
33.
Frick LR, Rapanelli M, Arcos ML, Cremaschi GA, Genaro AM. Oral administration of fluoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice. Eur J Pharmacol. 2011;659:265–72.CrossRefPubMed
34.
Liu F, Xie ZH, Cai GP, Jiang YY. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull. 2007;30(12):2279–83.CrossRefPubMed
35.
Cen J, Qi Y, Tao YF, Deng Y, Fang WR, Li YM, et al. HZ08, A great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM. Eur J Pharmacol. 2010;647:21–30.CrossRefPubMed
36.
Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta. 2002;1587:318–25.CrossRefPubMed
37.
Barbey JT, Roose SP. SSRI safety in over dose. J Clin Psychiatry. 1998;59:42–8.PubMed
Metadata
Title
Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells
Authors
Ting Zhou
Jingjing Duan
Yan Wang
Xin Chen
Ganping Zhou
Rongkan Wang
Liwu Fu
Feng Xu
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0377-4

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue

Research Article

The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer

Research Article

Mammalian Sulf1 RNA alternative splicing and its significance to tumour growth regulation

Research Article

The prognostic significance of tumor-associated stroma in invasive breast carcinoma

Research Article

Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours

Research Article

Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer

Research Article

Nuclear p63 expression in osteoblastic tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits